@Article{Jurczak2015,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="19",
number="3",
year="2015",
title="Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study",
abstract=" Aim of the study : PROFIL was a prospective observational study conducted to investigate physicians’ evaluation of febrile neutropenia (FN) risk and reasons for giving pegfilgrastim primary prophylaxis (PP) in routine clinical practice in Poland.    Material and methods : Adult cancer patients treated with chemotherapy (CT), assessed by investigators as having high overall FN risk, and who received pegfilgrastim in cycle 1 were enrolled between 03/2009 and 09/2010. Investigators assessed FN risk of the CT regimen, individual risk factors, and overall FN risk, and were asked to provide the most important reasons for providing pegfilgrastim PP. Investigator-assessed CT FN risk was compared with guideline classification.    Results : Data were analysed from 1006 breast, ovarian, and lung cancer, and non-Hodgkin (NHL) and Hodgkin lymphoma (HL) patients. The most important reasons for using pegfilgrastim PP were high CT FN risk and advanced disease; these were consistent across tumour types and treatment intent. The investigators generally assessed high CT FN risk in agreement with guideline classification. Febrile neutropenia occurred in 4% of patients, most commonly in HL, NHL, and patients with advanced disease.    Conclusions : High CT FN risk and advanced stage of disease were found to be the most important reasons for providing pegfilgrastim PP by physicians in Poland.",
author="Jurczak, Wojciech
and Kalinka-Warzocha, Ewa
and Chmielowska, Ewa
and Duchnowska, Renata
and Wojciechowska-Lampka, Elzbieta
and Wieruszewska, Karolina",
pages="214--219",
doi="10.5114/wo.2015.52657",
url="http://dx.doi.org/10.5114/wo.2015.52657"
}